Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL803211 | 0.93 | — | — | |
| SCHEMBL25921758 | 0.82 | NPC1 (0.30) | — | |
| SCHEMBL25921759 | 0.82 | NPC1 (0.30) | — | |
| SCHEMBL24339626 | 0.82 | NPC1 (0.30) | — | |
| SCHEMBL13857270 | 0.80 | TSHR (0.32) | TSHRNPSR1CYP19A1HCRTR2 | |
| SCHEMBL12014 | 0.80 | ALDH1A1 (0.33) | TSHRNPSR1CYP19A1HCRTR2 | |
| SCHEMBL13429399 | 0.80 | ALDH1A1 (0.33) | TSHRNPSR1CYP19A1HCRTR2 | |
| SCHEMBL8356702 | 0.80 | ALDH1A1 (0.33) | TSHRNPSR1CYP19A1HCRTR2 | |
| SCHEMBL13741232 | 0.76 | CYP19A1 (0.33) | TSHRNPSR1CYP19A1HCRTR2 | |
| SCHEMBL21757398 | 0.76 | TSHR (0.30) | TSHRNPSR1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022048684-A1 | JNK INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 武汉朗来科技发展有限公司 | 2022-03-10 | — | — | WO | disclosed |
| US-20170362506-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2017-12-21 | — | — | US | disclosed |
| US-20170335195-A1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2017-11-23 | — | — | US | disclosed |
| US-20170335194-A1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2017-11-23 | — | — | US | disclosed |
| EP-3246377-A1 | LIQUID-CRYSTAL MEDIUM | Merck Patent GmbH (DE) | 2017-11-22 | — | — | EP | disclosed |
| US-9777216-B2 | Liquid crystalline medium | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2017-10-03 | — | — | US | disclosed |
| US-20170253801-A1 | LIQUID-CRYSTAL MEDIA AND LIGHT MODULATION ELEMENT | MERCK PATENT GMBH (DE) | 2017-09-07 | — | — | US | disclosed |
| EP-3211059-A1 | LIQUID CRYSTAL DISPLAYS AND LIQUID CRYSTALLINE MEDIA WITH HOMEOTROPIC ALIGNMENT | Merck Patent GmbH (DE) | 2017-08-30 | — | — | EP | disclosed |
| US-9737854-B2 | Process for the purification of a liquid-crystal mixture | MERCK PATENT GMBH (DE) | 2017-08-22 | — | — | US | disclosed |
| US-9726933-B2 | Liquid-crystal displays and liquid-crystalline media having homeotropic alignment | MERCK PATENT GMBH (DE) | 2017-08-08 | — | — | US | disclosed |
| US-20080191166-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GESELLSCHAFT (DE) | 2008-08-14 | — | — | US | disclosed |
| US-20080191167-A1 | Liquid-crystalline medium | MERCK PATENT GMBH | 2008-08-14 | — | — | US | disclosed |
| US-20080193681-A1 | Liquid-Crystal Medium | MERCK PATENT GMBH (DE) | 2008-08-14 | — | — | US | disclosed |
| US-20080116419-A1 | Mesogenic Compounds, Liquid Crystal Medium and Liquid Crystal Display | MERCK PATENT GMBH (DE) | 2008-05-22 | — | — | US | disclosed |
| US-7371437-B2 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2008-05-13 | — | — | US | disclosed |
| US-20080090026-A1 | Liquid-crystal display | MERCK PATENT GMBH | 2008-04-17 | — | — | US | disclosed |
| US-7335403-B2 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2008-02-26 | — | — | US | disclosed |
| EP-1199346-B1 | Liquid crystal medium | MERCK PATENT GMBH (DE) | 2008-01-23 | — | — | EP | disclosed |
| US-20070080324-A1 | mixture of polar compounds of negative dielectric anisotropy; electro-optical display with active-matrix addressing based on the ECB(electrically controlled birefringence), PALC (positive charge assisted leakage current) or IPS ( in plane switching) effect | MERCK PATENT GMBH (DE) | 2007-04-12 | — | — | US | disclosed |
| US-20070051920-A1 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090026-A1 | Liquid-crystal display | KLK3, LPXN, BPHL | TSHR 4657/4885NPSR1 595/4885CYP19A1 1934/4885 |
| US-20080116419-A1 | Mesogenic Compounds, Liquid Crystal Medium and Liquid Crystal Display | CRY1, CRY2, IK | TSHR 4483/4885NPSR1 1222/4885CYP19A1 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.